

***Prof. Claudio Ferri***

**Curriculum  
dell'attività didattica e scientifica  
(corredato di dati biografici ed  
attività assistenziale)**



## ***Dati biografici***

### **Eta':**

nato a Roma il 20.6.1957.

### **Stato civile:**

Sposato con due figli.

### **Residenza:**

Via Ticino 5/A, 00198 Roma.

### **Domicilio:**

Viale San Salvatore – Edificio Delta 6 - 67100 L'Aquila

### **Qualifica attuale:**

*Accademica:* Professore Ordinario in Medicina Interna  
l'Università dell'Aquila

*Assistenziale:* Direttore U.O.C. Medicina Interna e Nefrologia  
Ospedale San Salvatore – L'Aquila

### **Afferenza attuale:**

*Accademica:* Università dell'Aquila – Dipartimento di Medicina  
Clinica, Sanità Pubblica, Scienza della Vita e dell'Ambiente (MeSVA)

*Assistenziale:* Ospedale San Salvatore (L'Aquila) – U.O.C. Medicina  
Interna e Nefrologia

## ***Studi:***

Maturita' scientifica (voto 60/60) – Liceo Plinio Seniore di Roma

Laurea in Medicina e Chirurgia (110/110 e lode) – Facolta' di Medicina e Chirurgia dell'Universita' degli Studi di Roma "La Sapienza" (1982)

Specializzazione in Medicina Interna (70/70 e lode) presso la Facolta' di Medicina e Chirurgia dell'Universita' degli Studi di Roma "La Sapienza" (1987).

Lingue parlate e scritte: italiano ed inglese.

Conoscenza scolastica del francese e dello spagnolo

## *Attività' assistenziale:*

1978-1982: Allievo interno presso il reparto di I Clinica Medica dell'Istituto di I Clinica Medica Generale e Terapia Medica dell'Università degli Studi di Roma "La Sapienza".

1982-1990: Specializzando e successivamente medico volontario presso il reparto di cui sopra.

1991: Successivamente alla presa di servizio – avvenuta con decorrenza giuridica 10.7.1990 ed economica 15.9.1990 come Collaboratore Tecnico VII livello – dall'1.11.1993 Funzionario Tecnico VIII livello – conferimento della qualifica assistenziale (decorrenza: 1.1.1991) presso la Divisione di I Clinica Medica Generale e Terapia Medica dell'Istituto di I Clinica Medica – Università degli Studi di Roma “La Sapienza”.

1991: Inizio attività' ambulatoriale specialistica presso il Servizio Divisionale di Fisiopatologia dell'Ipertensione Arteriosa della stessa struttura.

1991-1999: Continuazione attività assistenziale in corsia ed in ambulatorio, nelle istituzioni sopra citate. Tali attività hanno termine con la presa di servizio - in qualità di Professore Associato in Medicina Interna – presso l'Università di L'Aquila – Facoltà di Medicina e Chirurgia – avvenuta l'1.11.1999.

1999: Come vincitore di concorso per Professore Associato in Medicina Interna – chiamato dalla Facoltà di Medicina e Chirurgia dell'Università di L'Aquila (presa di servizio: 1.11.1999) – nelle more del perfezionamento convenzionale con la ASL allora AQ4 inizia a svolgere (dall'1.11.1999) attività assistenziale nel reparto - Medicina Interna Universitaria 1 dell'Università di L'Aquila – Facoltà di Medicina e Chirurgia – Ospedale San Salvatore.

2000: Ratifica dell'attività assistenziale (convenzionamento avvenuto in data 4.1.2000) che è tutt'ora svolta dal candidato. Promuove l'apertura dell'ambulatorio di “Ipertensione Arteriosa e Prevenzione Cardiovascolare” afferente alla struttura di cui sopra.

2003: Prosegue l'attività dirigenziale – come Professore Associato – in qualità però di Direttore dell'Unità Operativa Complessa di Medicina Interna Universitaria 1 – Ospedale San Salvatore. Questo in seguito al pensionamento del Mentore, la compianta Prof.ssa Anna Santucci, cui il Prof. Claudio Ferri deve tutto e cui è e sarà riconoscente per sempre.

2004: Prosegue la medesima attività, ma come vincitore di concorso per Professore Ordinario in Medicina Interna. Il concorso è stato vinto nel

2004, con chiamata avvenuta in data 01-11-2004 e presa di servizio presso l'Ateneo Aquilano in data 01-03-2005.

2013: La U.O.C. di Medicina Interna Universitaria 1 diviene U.O.C. di Medicina Interna e Nefrologia, con Direzione Universitaria sempre assegnata al Prof. Claudio Ferri per entrambe le specialità. La U.O.C. diretta dal Prof. Claudio Ferri è in atto strutturata in: 32 letti di degenza, di cui almeno 4 di nefrologia, 2 letti di Ospedale diurno, 5 ambulatori dedicati, attivi a turno 6 giorni su 7 dalle ore 09.00 alle ore 13.00 e dalle ore 14.30 alle ore 18.00 (Ipertensione Arteriosa e Prevenzione Cardiovascolare, Endocrinologia, Reumatologia, Medicina Interna, Nefrologia), 1 servizio per il monitoraggio ambulatorio della pressione arteriosa nelle 24 ore, 1 servizio di ecografia internistica, 1 servizio per la capillaroscopia, la valutazione della vasodilatazione endotelio-dipendente e della morfologia/funzione vascolare periferica e centrale.

*Oltre a quanto sopra il Prof. Claudio Ferri è stato oppure è:*

Senatore Accademico (dall'1.11.2007 al 31.12.2008: dimessosi per la sopraggiunta incompatibilità tra Direzione della Scuola di Specializzazione in Medicina Interna, che ha sempre mantenuto, e l'incarico di Direttore del Dipartimento di Medicina Interna e Sanità Pubblica, cui ha invece rinunciato, come già scritto, per mantenere la Direzione della Scuola)

Membro della Commissione regionale per il farmaco (dal Novembre 2007). Il rinnovo dell'accettazione dell'incarico è avvenuto il giorno 09.02.2016

Direttore del Dipartimento di Medicina Interna e Sanità Pubblica (dall'1-11-2004 al 31.12.2008).

Presidente del Consiglio dei Clinici dell'Ateneo dall'1.2.2011 al 30.10 2013.

Dall'Ottobre 2013 – essendo stato abolito nel nuovo Statuto di Ateneo il Consiglio dei Clinici e rifondata la commissione paritetica – è membro Universitario della commissione paritetica ASLAQ01-Università dell'Aquila

Dal 2013 è membro effettivo, quale Clinico Universitario (precedentemente era consulente clinico) del Comitato Etico della ASLAQ1.

## *Attività didattica:*

1987-1999: Attività tutoriale presso il reparto di I Clinica Medica dell'Istituto di I Clinica Medica Generale e Terapia Medica dell'Università degli Studi di Roma "La Sapienza".

1987-1999: Seminari per studenti e specializzandi nella struttura di cui sopra.

1987/1988: Corso annuale di Clinica delle Minorazioni nel corso biennale di specializzazione polivalente per personale direttivo, docente ed educativo ai fini dell'insegnamento agli handicappati, autorizzato con D.M. 7.11.1987.

1988-1999: Preparazione delle lezioni di Clinica Medica svolte dal Direttore della Cattedra.

1993/1994 Professore a contratto del corso integrativo di Metodologia Clinica e Semeiotica Medica - corso ufficiale Medicina Interna - nel corso di laurea in Odontoiatria e Protesi dentaria della Facoltà di Medicina e Chirurgia dell'Università degli Studi di L'Aquila.

1994/1995 Professore a contratto del corso integrativo di Metodiche diagnostiche nella malattia ipertensiva - corso ufficiale Nefrologia Medica - nel corso di Laurea in Medicina e Chirurgia della suddetta Facoltà.

1995/1996 e 1996/1997 Professore a contratto del corso integrativo di Tecniche di studio di fisiopatologia cardiopolmonare - corso ufficiale Fisiopatologia Cardiopolmonare - nella Scuola di Specializzazione in Cardiologia della suddetta Facoltà.

1997/98 Professore a contratto del corso integrativo di Tecniche di studio di fisiopatologia cardiopolmonare - corso ufficiale Fisiopatologia Cardiopolmonare - nella Scuola di Specializzazione in Cardiologia della suddetta Facoltà.

Dall' VIII ciclo permanentemente fino al ciclo attualmente in corso: Esperto nel Dottorato di Ricerca in Medicina Interna con sedi consorziate L'Aquila e Roma (dalla presa di servizio presso l'Ateneo Aquilano è docente nello stesso Dottorato di Ricerca, con sede in

L'Aquila, che ha assunto la definizione di “Medicina Interna ed Immunologia Clinica”).

Successivamente alla presa di servizio nell'Ateneo di L'Aquila come Professore Associato in Medicina Interna (concorso vinto nel 1999, presa di servizio avvenuta l'1.11.1999) ha iniziato ad insegnare nel corso di Laurea specialistica in Medicina, in altri Corsi di Laurea e nelle Scuole di Specializzazione e ha continuato tale attività come Professore Ordinario in Medicina Interna (concorso vinto nel 2004, presa di servizio avvenuta il 01.03.2005).

Dall' Anno Accademico 2005-2006 è Direttore della Scuola di Specializzazione in Medicina Interna e Coordinatore del Dottorato in Medicina Interna ed Immunologia Clinica (incarico terminato con la soppressione di tale Dottorato e la confluenza in quello di Medicina Clinica e Sanità Pubblica).

Dal Dicembre 2018 è coordinatore del Dottorato di ricerca in Medicina Clinica e Sanità Pubblica dell'Ateneo dell'Aquila – Dipartimento MeSVA

Attualmente, è Membro del Consiglio Didattico del Corso di Laurea in Medicina e Chirurgia. Come Professore Ordinario in Medicina Interna (chiamata avvenuta in data 01-11-2004 e presa di servizio presso l'Ateneo Aquilano avvenuta in data 01-03-2005), insegna:

### ***Corso di Laurea Specialistica in Medicina e Chirurgia***

Corso Integrato (CI) di Malattie del rene e delle vie urinarie:

*Nefrologia*

Corso Integrato di Semeiotica e Metodologia clinica: *Semeiotica generale e metodologia clinica*

Corso Integrato (CI) di Medicina Interna II e Geriatria: *Medicina Interna*

Corso Integrato (CI) di Medicina Interna III e Geriatria: *Medicina Interna*

Corso Integrato (CI) di Medicina Interna, endocrinologia,  
immunologia clinica e malattie infettive: *Malattie del rene e  
dell'apparato cardiovascolare*

### *Scuole di Specializzazione*

- Medicina Interna (di cui è Direttore)

*Medicina Interna*

- Urologia

*Patologia integrata e semeiotica funzionale e strumentale:*

*Nefrologia*

- Chirurgia maxillo-facciale

*Patologia medica e chirurgia testa collo: Patologia medica*

*testa-collo*

- Geriatria

*Malattie metaboliche e del ricambio*

- Oncologia Medica

*Nefrologia*

- Otorinolaringoiatria

*Patologia medica testa-collo*



- Radiodiagnostica e Radioterapia

*Clinica e Chirurgia in Diagnostica per immagini e*

*Radioterapia: il trattamento medico delle patologie dei vari*

*organi ed apparati*

### *Attività Societaria:*

Socio ordinario della Società Italiana di Medicina Interna, della Società Italiana dell'Ipertensione Arteriosa e della Società Italiana di Prevenzione Cardiovascolare.

Consigliere nazionale e già tesoriere della Società Italiana dell'Ipertensione Arteriosa.

Attualmente è Presidente della medesima Società.

Consigliere nazionale della Società Italiana di Prevenzione Cardiovascolare

Membro del Council for High Blood Pressure Research della American Heart Association.

Membro della European Society of Hypertension.

Clinic Hypertension Specialist della European Society of Hypertension (qualifica conferita su invito della Società Europea, dietro indicazione della Società Italiana dell'Ipertensione Arteriosa).

## ***Riviste e attività di reviewer***

Reviewer per il Congresso annuale della Società Italiana dell'Iperensione Arteriosa.

Reviewer per il Congresso della Società Europea dell'Iperensione Arteriosa.

Reviewer per Circulation, Journal of Hypertension, Diabetes, Diabetes Care, Diabetologia etc.

Membro del board di "Iperensione Arteriosa e Prevenzione Cardiovascolare".

Membro del board di Nutrition, Metabolism and cardiovascular disease

Membro del board di Journal of Hypertension

Membro del board di International Journal of Cardiology - Hypertension

Revisore dei progetti di finanziamento del Ministero dell'Università e della Ricerca Scientifica.

## *Attività scientifica*

L'attività scientifica del Prof. Ferri è provata, oltre che dai numerosi progetti nazionali ed internazionali cui prende parte oppure coordina e dall'intensa attività congressuale nazionale ed internazionale come relatore invitato, da 255 pubblicazioni a stampa su riviste peer reviewed. Il Prof. Ferri è anche autore di circa 300 pubblicazioni in lingua italiana, che non vengono qui elencate per brevità espositiva e perché la loro lista cartacea e su file è andata smarrita per il crollo dello studio personale nel sisma aquilano del 2009.

Oltre a quanto sopra, il Prof. Ferri ha curato la traduzione di numerosi libri di uso comune per studenti in Medicina e specializzandi in Medicina Interna ed in Cardiologia ed è co-autore di diversi libri per studenti, ultimo uscito nel 2013 il libro "La nutraceutica" edito dall'Ateneo di Bologna.

Il Prof. Ferri fruisce oppure ha fruito di molteplici finanziamenti nazionali ed internazionali, finalizzati alla conduzione di studi clinici e/o sperimentali. Ultimi finanziamenti dalla Azienda Unilever per uno studio sugli effetti cardiovascolari del tè e dalla Fondazione Carispaq per uno studio da condursi nel territorio aquilano.

I filoni di ricerca dell'attività scientifica svolta dal prof. Ferri hanno riguardato principalmente il metabolismo del sodio nel contesto della etiopatogenesi e terapia dell'ipertensione arteriosa, la funzione endoteliale e – da circa 10 anni – il ruolo dell'alimentazione e di alcuni micro- e macronutrienti nell'influenzare la regolazione pressoria e la sensibilità insulinica. Molti tra gli studi svolti dal Prof. Ferri sono condotti insieme a prestigiosi gruppi di ricerca nazionali ed internazionali.

## *Pubblicazioni peer reviewed*

*(H index SCOPUS = 51, citazioni SCOPUS = 10955)*

1) Relationship between vasopressin and the renin angiotensin aldosterone system in essential hypertension: effect of converting enzyme inhibition on plasma vasopressin. A.Santucci, R.Leonetti Luparini, *Claudio Ferri*, C.Ficara, C.Giarrizzo. J Hypertens 1985, 3(suppl 2):S133-S134.

- 2) Comparative study of the antihypertensive efficacy of fixed combinations of hydrochlorothiazide either with captopril or amiloride. C.Giarrizzo, C.Ficara, *Claudio Ferri*, R.Leonetti Luparini, G.Botta, A.Santucci. *Curr Ther Res* 1988, 44,5:731-736.
- 3) Effects of angiotensin converting enzyme inhibition on platelet angiotensin II content. A.Santucci, *Claudio Ferri*, R.Leonetti Luparini, MA Del Porto, C.De Angelis, C.Ficara, F.Balsano. *Am J Med* 1988, 84(suppl 3A):119- 121.
- 4) Effect of nicardipine on angiotensin II platelet content. *Claudio Ferri*, A. Santucci, R. Leonetti Luparini, MA Del Porto, C. De Angelis, C. Giarrizzo, C. Ficara e F. Balsano. *JHypertens* 6 (suppl 1):S117-S119, 1988.
- 5) Blood platelets and angiotensin II: angiotensin II release after platelet aggregation. *Claudio Ferri*, C. De Angelis, MA Del Porto, R. Leonetti Luparini, C. Giarrizzo, A. Santucci, F. Balsano. *J Hypertens* 1988, 6(suppl 1):S69-s71.
- 6) Captopril does not alter metabolic control in elderly hypertensive diabetics during secondary failure. G. De Mattia, O. Laurenti, G. Tullo, R. Ziantoni, *Claudio Ferri*, C. Ventura, *J Hypertens* 1988, 6(suppl 1):S113-S115.
- 7) Hypertensive emergencies in old age: effects of angiotensin converting enzyme inhibition. V. Marigliano, D. Santilli, M. Fiorani, M. Cacciafesta, *Claudio Ferri*, G. Piccirillo. *J Hypertens* 1988, 6(suppl 1):S91-S93.
- 8) Evidence for sidedness of the baroreceptor regulation of atrial natriuretic peptide in normal human subjects. A.Santucci, V.Marigliano, I.Cammarella, *Claudio Ferri*, R.Leonetti Luparini, C.De Angelis. In: "Progress in atrial peptide research" Eds. Brenner BM, Laragh JH, Raven Press, New York 1989, 476- 480 (NB: trattasi di articolo edito in un libro, e non pubblicato su rivista).
- 9) Angiotensin converting enzyme and quality of life: a randomized controlled trial. A. Santucci, F. Puccetti, C. Ficara, M. Franchi, C. Giarrizzo, F. Landini, *Claudio Ferri*, G. Botta, T. Di Perri. *Curr Ther Res* 1989, 46,5:849-857.
- 10) A comparison of the metabolic effects of short-term treatment with captopril, hydrochlorothiazide, and captopril plus hydrochlorothiazide in patients with essential hypertension. *Claudio Ferri*, C.Giarrizzo, R. Leonetti Luparini, G. Germano', A. Buonanno, A. Santucci, F. Balsano. *Advances in Therapy* 1989, 6,5: 237-241.
- 11) Modulatory role of the peripheral dopaminergic system on factors regulating renal sodium handling in elderly hypertensive patients. C. Giarrizzo, C. Ficara, C. De Angelis, *Claudio Ferri*, R. Leonetti Luparini, R. Onofri, V. Marigliano, A. Santucci. *Curr Ther Res* 1989, 46,5:903-907.
- 12) Influence of angiotensin converting enzyme inhibition on psychometric tests in elderly hypertensives. D. Santilli, E. Bagaglini M. Cacciafesta, *Claudio Ferri*, D. Brioli, V. Marigliano. *Curr Ther Res* 1989, 45,1:128-132.
- 13) Antihypertensive efficacy of low-dosage angiotensin converting enzyme inhibition in elderly patients with mild or moderate hypertension. V. Marigliano, M. Cacciafesta, *Claudio Ferri*, G. Piccirillo, D. Santilli, E. Bagaglini. *Curr Ther Res* 1989, 46,1:180-186.
- 14) Long-term captopril treatment in elderly hypertension. V. Marigliano, D. Santilli, L. Meliffi, M. Cacciafesta, *Claudio Ferri*, G. Piccirillo, F. Robinson, A. Tagliaccica, G. Tagliaccica. *Curr Ther Res* 1989, 46,5:858-865.

**15)** Plasma atrial natriuretic peptide in young hypertensives and in young normotensives subjects with a family history of hypertension and in young hypertensive patients. A. Santucci, *Claudio Ferri*, I. Cammarella, S. Tani, A. Musca, F. Balsano. *Am J Hypert* 1990 3:10-15.

**16)** Atrial natriuretic factor behaviour in hypertensive diabetic patients. G. De Mattia, *Claudio Ferri*, M. Tullo, O. Laurenti, C. Giarrizzo, C. Ventura, A. Santucci. In: *Diabetes, obesity and hyperlipidemias - IV*. Crepaldi G, Tiengo A, Enzi G (Eds.). Elsevier Science Publishers B.V. (Biomedical Division) 1990, 451-453. (NB: trattasi di articolo edito in un libro, e non pubblicato su rivista).

**17)** Efficacy and safety evaluation of a fixed combination of captopril 50 mg/hydrochlorothiazide 15 mg in hypertensive diabetic patients. A. Santucci, G. De Mattia, C. Giarrizzo, O. Laurenti, *Claudio Ferri*, A. Piccoli, G. Botta, F. Balsano. *Advances in Therapy* 1990, 7,1:28-32.

**18)** Efficacy and safety of nitrendipine therapy in moderate essential hypertension. C. Giarrizzo, *Claudio Ferri*, G. Germano', R. Leonetti Luparini, MA Del Porto, C. Bellini, A. Santucci, F. Balsano. *Advances in Therapy* 1990,7,1:38:42.

**19)** Once-daily administration of captopril plus hydrochlorothiazide in patients with essential hypertension. A biometrical approach for investigating its effects on blood-pressure circadian rhythm. G. Germano', S. Damiani, V. Pecchioli, U. Germano', C. Giarrizzo, *Claudio Ferri*, R. Leonetti Luparini, A. Santucci, F. Balsano. *Curr Ther Res* 1990, 47, 6:940-951.

**20)** Circadian Blood pressure, heart rate, and endocrine variations in young healthy and mesor- hypertensive men. G. Germano', *Claudio Ferri*, I. Cammarella, C. Bellini, A. Santucci, A. Germani, A. Musca, F. Balsano, Y Li, G. Cornelissen, F. Halberg. In: *New Trends in Autonomic nervous system research*. Yoshikawa M et al EDS, Elsevier 1991 576-580. (NB: trattasi di articolo edito in un libro, e non pubblicato su rivista).

**21)** Effects of dopamine infusion on plasma atrial natriuretic peptide in normal subjects. A. Piccoli, A. Carlomagno, *Claudio Ferri*, C. Bellini, R. Leonetti Luparini, C. Giarrizzo, L. Di Francesco, A. Santucci, F. Balsano. *Curr Ther Res* 1991, 50, 6:780-785.

**22)** Sodium metabolism during altitude acclimatization. C. De Angelis, S. Farrace, L. Urbani, S. Porcu', *Claudio Ferri*, R. D'Amelio. *Med Aer Spatial* 1991, 30,119:309-314.

**23)** Does mild autonomic neuropathy affect atrial natriuretic factor regulation in diabetic hypertensive patients ? G. De Mattia, O. Laurenti, C. Bravi, *Claudio Ferri*, C. Bellini, C. De Angelis, C. Giarrizzo, A. Santucci, F. Balsano. *Am J Hypertens* 1991, 4:832-835.

**24)** Plasma insulin levels do not change during atrial natriuretic factor infusion in human essential hypertensives. *Claudio Ferri*, G. De Mattia, A. Piccoli, A. Carlomagno, R. Leonetti Luparini, G. Germano', C. Giarrizzo, G. Torregrossa, A. Santucci, F. Balsano. *Am J Hypertens* 1991, 4:880-884.

**25)** <sup>23</sup>Na-NMR study of cation cotransport in human red blood cells. M. Cacciafesta, V. Marigliano, *Claudio Ferri*, G. Piccirillo, L. Guidoni, AM. Luciani, A. Rosi, V. Viti. *Am J Physiol* 1992, 262 (Cell Physiol): 1292-1296

**26)** Natriuretic hormones in young hypertensives and in young normotensives with or without a family history of hypertension. A. Musca, I. Cammarella, *Claudio Ferri*, C.

Bellini, R. Ruggeri, A. Santucci, F. Balsano. *Am J Hypertens* 1992, 5:592-599.

**27)** Blood pressure nyctohemeral rhythm changes in early and intermediate stages of renal failure. G. Germano', S. Damiani, U. Germano', C. Giarrizzo, *Claudio Ferri*, R. Leonetti Luparini, A. Santucci, F. Balsano. *J Ambulat Monit* 1992, 5,1:41-50.

**28)** <sup>23</sup>Na NMR evaluation of human erythrocytes Na<sup>+</sup>/K<sup>+</sup>/Cl<sup>-</sup> cotransport. A study in elderly hypertensives. M. Cacciafesta, *Claudio Ferri*, G. Piccirillo, C. Bellucci, L. Persichino, V. Marigliano, M. Delfini, A. Miccheli. *Cell Mol Biol* 1992, 32(8):877-884.

**29)** Effects of high altitude exposure on plasma and urinary digoxin-like substance. C. De Angelis, S. Farrace, L. Urbani, S. Porcu', *Claudio Ferri*, R. D'Amelio, A. Santucci, F. Balsano. *Am J Hypertens* 1992, 5:600-607.

**30)** Enhanced blood pressure response to cyclooxygenase inhibition in salt-sensitive human essential hypertension. *Claudio Ferri*, C. Bellini, A. Piccoli, A. Carlomagno, MS Bonavita, A. Santucci, F. Balsano. *Hypertension* 1993, 21:875-881

**31)** Octreotide, a somatostatin analog, reduces insulin secretion and increases renal Na<sup>+</sup> excretion in lean essential hypertensive patient. *Claudio Ferri*, G. De Mattia, C. Bellini, O. Laurenti, C. Bravi, R. Baldoncini, M.S. Bonavita, A. Santucci. *Am J Hypertens* 1993, 6:276-281.

**32)** The influence of salt sensitivity on the blood pressure response to exogenous kallikrein in essential hypertensive patients. C. Bellini, *Claudio Ferri*, A. Piccoli, A. Carlomagno, L. Di Francesco, MS Bonavita, A. Santucci, F. Balsano. *Nephron* 1993, 65:28-35.

**33)** Oxygen administration increases plasma digoxin-like substance and renal sodium excretion in chronic hypoxic patients. C. De Angelis, A. Perrone, *Claudio Ferri*, A. Piccoli, C. Bellini, R. D'Amelio, A. Santucci, F. Balsano. *Am J Nephrol* 1993, 13:173-177.

**34)** Renal sodium excretory function during acute oxygen administration. L. De Siati, R. Baldoncini, C. De Angelis, *Claudio Ferri*, A. Santucci, A. Perrone, F. Balsano. *Respiration* 1993, 60:338-342.

**35)** Increased sodium,potassium cotransport activity in salt-sensitive essential hypertensive patients. M. Cacciafesta, *Claudio Ferri*, A. Carlomagno, G. Piccirillo, C. De Angelis, A. Santucci, L. Guidoni, AM Luciani, A. Rosi, V. Viti, F. Balsano. *J Hypertens* 1993, 11(Suppl 5):S254-S255.

**36)** Urinary kallikrein excretion and plasma atrial natriuretic peptide in human salt-sensitive hypertension. *Claudio Ferri*, C.Bellini, A.Carlomagno, L.De Siati, A.Perrone, A.Santucci, F.Balsano. *J Hypertens* 1993,11(Suppl 5):212-3.

**37)** Effects of short-time insulin suppression on renal sodium excretion in type II diabetic hypertensives. A. Porzano, C. Bellini, *Claudio Ferri*, O. Laurenti, G. De Mattia, A. Santucci, F. Balsano. *Diab Res* 1993, 22:3-10.

**38)** Atrial natriuretic peptide in non-modulating essential hypertension. R. Leonetti Luparini, *Claudio Ferri*, A. Santucci, F. Balsano. *Hypertension* 1993, 21:803-809.

**39)** Salt-sensitivity is associated with a hyperinsulinaemic and hyperglycaemic response to atrial natriuretic peptide infusion in human essential hypertension. *Claudio Ferri*, C. Bellini, G. Desideri, L. Di Francesco, G. de Mattia, A. Santucci, F.

Balsano. *Diabetologia* 1994, 37:308-312.

**40)** Abnormal atrial natriuretic peptide and renal responses to saline infusion in nonmodulating essential hypertensive patients. *Claudio Ferri*, C. Bellini, R. Baldoncini, R. Leonetti Luparini, A. Perrone, A. Santucci. *Circulation* 1994, 90:2859-2869.

**41)** Erythrocyte Na-K-Cl cotransport activity in low renin essential hypertensive patients. A <sup>23</sup>Na Nuclear Magnetic Resonance study. M. Cacciafesta, *Claudio Ferri*, A. Carlomagno, C. De Angelis, L. Guidoni, AM Luciani, A. Rosi, V. Viti, A. Santucci, F. Balsano. *Am J Hypertens* 1994, 7:151-158.

**42)** Atrial natriuretic factor in hypertensive and normotensive diabetic patients. *Claudio Ferri*, A. Piccoli, C. Bellini, O. Laurenti, G. De Mattia, A. Santucci, F. Balsano. *Diabetes Care* 1994, 3: 195-200.

**43)** Influence of the renin profile on the blood pressure response to different doses of hydrochlorothiazide plus either quinapril or captopril. *Claudio Ferri*, L. Di Francesco, A. Perrone, R. Baldoncini, G. Veneto, G. Raule, C. Bellini. *Drug Invest* 1994, 7(6):340-345.

**44)** Urinary kallikrein and salt sensitivity in essential hypertensive males. *Claudio Ferri*, C. Bellini, A. Carlomagno, A. Perrone, A. Santucci. *Kidney Int* 1994, 46:780-788.

**45)** Plasma endogenous digoxin-like substance levels are dependent on blood O<sub>2</sub> in man. *Claudio Ferri*, C. Bellini, C. De Angelis, A. Perrone, A. Santucci. *Clin Sci* 1994, 87:447-451.

**46)** Effects of atrial natriuretic factor infusion on plasma prorenin levels in hypertensive males. R. Baldoncini, *Claudio Ferri*, L. De Siatì, C. Bellini, A. Santucci. *Clin Exp Hypertens* 1994, 16(3):283-302.

**47)** Abnormal atrial natriuretic peptide and renal responses to saline infusion in nonmodulating essential hypertensive patients. *Claudio Ferri*, C. Bellini, R. Baldoncini, R. Leonetti Luparini, A. Perrone, A. Santucci. *Circulation* 1994, 90:2859-2869.

**48)** Plasma endothelin-1 levels in obese hypertensive and normotensive men. *Claudio Ferri*, C. Bellini, G. Desideri, L. Di Francesco, R. Baldoncini, A. Santucci, G. de Mattia. *Diabetes* 1995, 44:431-436.

**49)** Circulating endothelin-1 levels in lean non- insulin-dependent diabetic patients. Influence of ACE- inhibition. *Claudio Ferri*, O. Laurenti, C. Bellini, MR Cassone Faldetta, G. Properzi, A. Santucci, G. De Mattia. *Am J Hypertens* 1995, 8:40-46.

**50)** Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in NIDDM men. *Claudio Ferri*, A. Carlomagno, R. Baldoncini, MR Cassone Faldetta, O. Laurenti, G. Properzi, A. Santucci, G. De Mattia. *Diabetes Care* 1995, 18:226-233.

**51)** The effect of insulin on endothelin-1 (ET-1) secretion in human cultured endothelial cell (letter). *Claudio Ferri*, G. De Mattia. *Metabolism* 5, 1995:689-690.

**52)** Hormonal and renal responses to atrial natriuretic peptide infusion in low renin hypertension. *Claudio Ferri*, R. Baldoncini, C. Bellini, L. Di Francesco, R. Leonetti Luparini, A. Santucci. *Am J Nephrol* 1995, 15:222-229.



- 53)** Circulating endothelin-1 concentrations in patients with chronic hypoxia. *Claudio Ferri, C. Bellini, C. De Angelis, L. De Sisti, A. Perrone, G. Properzi, A. Santucci. J Clin Pathol 1995, 48:519-524.*
- 54)** Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in vivo in patients with mediterranean spotted fever. G. Davi, Vigneri S, Ganci A, *Claudio Ferri, Di Francesco L, Vitale G, Mansueto S. Thromb Haemostas 1995, 74(2):631-634.*
- 55)** Active kallikrein response to changes in sodium chloride intake in essential hypertensive patients. *Claudio Ferri, C. Bellini, A. Carlomagno, G. Desideri, A. Santucci. J Am Soc Nephrol 1996, 7:443-453.*
- 56)** Impaired inactive to active kallikrein conversion in human salt sensitive hypertension. C. Bellini, *Claudio Ferri, A. Carlomagno, S. Necozone, A. Lepore, G. Desideri, A. Santucci. J Am Soc Nephrol 1996, 7:2565-2577.*
- 57)** Effect of aprotinin on insulin sensitivity in non- insulin-dependent diabetes mellitus. O. Laurenti, A. Piccoli, C. Bravi, M. Cassone Faldetta, C. Bellini, *Claudio Ferri, G. De Mattia. Diabetic Medicine 1996.*
- 58)** Plasma and urinary digitalis-like substance levels during atrial natriuretic peptide infusion in essential hypertensive patients. R. Baldoncini, *Claudio Ferri, C. Bellini, G. Desideri, C. De Angelis, A. Santucci. Clin Invest Med 1996, 19,1:1-16*
- 59)** Circulating catecholamines and metabolic effects of captopril effects of captopril in NIDDM patients. G. De Mattia, *Claudio Ferri, O. Laurenti, M. Cassone Faldetta, A. Piccoli, A. Santucci. Diabetes Care 1996, 19,3:226-230*
- 60)** Endogenous insulin modulates circulating endothelin-1 concentrations in humans. *Claudio Ferri, C. Bellini, G. Desideri, G. De Mattia, A. Santucci. Diabetes Care 1996, 19:504-506*
- 61)** Elevated levels of plasma endothelin-1, von Willebrand Factor, and urinary albumin excretion in three relatives with pseudoxanthoma elasticum. A. Piccoli, D Ricciardi, A. Santucci, V. Barnaba, *Claudio Ferri. Thromb Haemostas 1996, 76(2)275-277*
- 62)** Dysfonction endothéliale dans l'hipertension artérielle sensible au sel.. *C. Ferri, C. Bellini, G. Desiseri, L. Di Francesco, G. De Mattia, A. Santucci. Arch. Mal Coeur Vaiss. 1996, 89:971-974.*
- 63)** Effect of acute exposure to hypoxia on electrolytes and water metabolism regulatory hormones. C. De Angelis, *Claudio Ferri, L. Urbani, S. Farrace. Aviat Space Environ Med 1996, 67:746-750*
- 64)** Elevated albumin excretion in nonmodulating essential hypertensive patients. R. Baldoncini, C. Bellini, G. Desideri, C. De Angelis, *Claudio Ferri, A. Santucci. Nephron 1997, 76:264-269*
- 65)** Elevated plasma and urinary endothelin-1 levels in human salt-sensitive hypertension. *Claudio Ferri, C. Bellini, G. Desideri, C. Mazzocchi, L. De Sisti, A. Santucci. Clin Sci 1997, 93:35-41*
- 66)** Circulating endothelin-1 levels in obese patients with the metabolic syndrome. *Claudio Ferri, C. Bellini, G. Desideri, R. Baldoncini, G. Properzi, A. Santucci, G. De*

**67)** Increased levels of plasma endothelin-1 in non-insulin-dependent diabetic patients with retinopathy but without other diabetes-related organ damage. O. Laurenti, EM Vingolo, G Desideri, *Claudio Ferri*, C. Bellini, M. Cassone, A. Santucci, G. De Mattia. *Exp Clin Endocrinol Diabetes* 1997 105(Suppl 2):41-42

**68)** Poliol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. MC Bravi, P.Pietrangeli, O. Laurenti, MC Cassone-Faldetta, Claudio Ferri, Giancarlo De Mattia. *Metabolism* 1997, 46:1194-1198

**69)** Isolation and characterization of a digoxin-like immunoreactive substance from human urine by affinity chromatography. C. De Angelis, M. Riscuzzi, R. Salvini, A. Piccoli, *Claudio Ferri*, A. Santucci. *Clin Chem* 1997, 43:1416-1420

**70)** Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction. S. Francavilla, G. Properzi, C. Bellini, *Claudio Ferri*, A. Santucci. *J Urol* 1997, 158:1770-1774

**71)** Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion. In vitro and in vivo studies. G. Desideri, *Claudio Ferri*, C. Bellini, G. de Mattia, A. Santucci. *Diabetes* 1997, 46:81-86.

**72)** Elevated plasma endothelin-1 levels as an additional risk factor in non-obese essential hypertensive patients with metabolic abnormalities. *Claudio Ferri*, C. Bellini, G. Desideri, R. Baldoncini, L. de Siati, A. Santucci. *Diabetologia* 1997 40:100-102.

**73)** Age, gender, and non-modulation. A sexual dimorphism in essential hypertension. N.D.L. Fisher, *Claudio Ferri*, C. Bellini, A. Santucci, R. Gleason, G.H. Williams, N.K. Hollenberg, E.W. Seely. *Hypertension* 1997, 29:980-985.

**74)** Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. G. De Mattia, M. Cassone Faldetta, C. Bellini, O. Laurenti, R. Baldoncini, A. Santucci, *Claudio Ferri*. *Am J Hypertens* 1998, 11:983-988.

**75)** Influence of reduced glutathione infusion on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. G. De Mattia, MC Bravi, O. Laurenti, M. Cassone-Faldetta, A. Armiento, *Claudio Ferri*, F. Balsano. *Metabolism* 1998, 8:993-997.

**76)** Age, gender, and non-modulation. A sexual dimorphism in essential hypertension. N.D.L. Fisher, *Claudio Ferri*, C. Bellini, A. Santucci, R. Gleason, G.H. Williams, N.K. Hollenberg, E.W. Seely. *Hypertension* 1997, 29:980-985.

**77)** Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidemic, normotensive patients with non-insulin-dependent diabetes. G. De Mattia, M.C. Bravi, O. Laurenti, M Cassone-Faldetta, A. Proietti, O. De Luca, A. Armiento, *Claudio Ferri*. *Diabetologia* 1998, 41:1392-1396.

**78)** Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension. Influence of dietary sodium load and depletion. *Claudio Ferri*, C. Bellini, G. Desideri, E. Giuliani, L. De Siati, S. Cicogna, A. Santucci. *Hypertension* 1998, 32:862-868.

**79)** Enhanced activity of sodium-lithium countertransport in patients with cardiac

- syndrome X: a potential link between cardiac and metabolic syndrome X. A. Gaspardone, *Claudio Ferri*, F. Crea, F. Versaci, F. Tomai, A. Santucci, L. Chiarello, P.A. Giofrè. *J Am Coll Cardiol* 1998, 32:2031-2034.
- 80)** Angiotensin II increases the release of endothelin-1 from cultured endothelial cells but does not regulate its circulating levels. *Claudio Ferri*, G. Desideri, R. Baldoncini, M. Valenti, A. Santucci, G. De Mattia. *Clin Sci* 1999, 95:261-270.
- 81)** Effects of naloxone on myocardial ischemic preconditioning in man. F. Tomai, F. Crea, A. Gaspardone, F. Versaci, AS Ghini, *Claudio Ferri*, G. Desideri, L. Chiariello, PA Giofrè. *J Am Coll Cardiol* 1999, 33:1863-1869.
- 82)** Decreased activity of the red blood cell ATPase-dependent Na<sup>+</sup> pump in patients with cardiac syndrome X. *Claudio Ferri*, G. Desideri, G. de Mattia, C. Bellini, M. Gentile, P. Giofrè, A. Santucci, A. Gaspardone. *Clin Sci* 1999, 97:369-375.
- 83)** High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients. R. Baldoncini, G. Desideri, C. Bellini, M. Valenti, G. de Mattia, A. Santucci, *Claudio Ferri*. *Kidney Int* 1999, 56:1499-1504.
- 84)** Relationship between insulin resistance and nonmodulating hypertension. Linkage of metabolic abnormalities and cardiovascular risk. *Claudio Ferri*, C. Bellini, G. Desideri, M. Valenti, G. de Mattia, A. Santucci, N.K. Hollenberg, G.H. Williams. *Diabetes* 1999; 48:1623-1630.
- 85)** Altered adrenal sensitivity to angiotensin II in low renin essential hypertension. N.D.L. Fisher, S. Hurwitz, *Claudio Ferri*, X. Jeunemaitre, N.K. Hollenberg, G.H. Williams. *Hypertension* 1999, 34:388-394 (Articolo con commento editoriale di DG Warnock).
- 86)** Effects of insulin on in vitro vascular cell adhesion molecule-1 expression and in vivo soluble VCAM-1 release. G. de Mattia, M.C. Bravi, A. Costanzo, O. Laurenti, M. Cassone Faldetta, A. Armiento, O. De Luca MD, *Claudio Ferri*. *Diabetologia* 1999, 42:1235-1239.
- 87)** Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. L. Pastore, A. Tessitore, S. Martinotti, E. Toniato, E. Alesse, M.C. Bravi, *Claudio Ferri*, G. Desideri, A. Gulino, A. Santucci. *Circulation* 1999, 100:1646-1652.
- 88)** Early up-regulation of endothelial adhesion molecules in obese hypertensive men. *Claudio Ferri*, G. Desideri, M. Valenti, C. Bellini, A. Santucci, G. de Mattia. *Hypertension* 1999, 34:568-573.
- 89)** Prediction and consistency of blood pressure salt-sensitivity as assessed by a rapid volume expansion and contraction protocol. Salt-Sensitivity Study Group of the Italian Society of Hypertension. Strazzullo P, Galletti F, Dessi-Fulgheri P, *Claudio Ferri*, Glorioso N, Malatino L, Mantero F, Manunta P, Semplicini A, Ghiadoni L, Zoccali C. *J Nephrol* 2000, 13(1):46-53
- 90)** Renal endothelin-1 is linked to changes in urinary salt and volume in essential hypertension. L. Malatino, I. Bellanuova, A. Cataliotti, F. Cuzzola, F. Mallamaci, G. Tripepi, S. Parlongo, S. Cutrupi, R. Mangiafico, *Claudio Ferri*, F. Galletti, N. Glorioso, P. Strazzullo, C. Zoccali on behalf of the SISS Group of the Italian Society of Hypertension. *J Nephrol* 2000, 13:178-184.
- 91)** Circulating vascular endothelial growth factor levels are decreased in patients with chronic and liver cirrhosis depending on the degree of hepatic damage. G.

Desideri, *Claudio Ferri*. Clin Sci 2000, 99:159-160.

**92)** Endothelial activation in patients with cardiac syndrome X. G. Desideri, A. Gasparone, M. Gentile, A. Santucci, P.A. Gioffrè, *Claudio Ferri*. Circulation 2000, 102:2359-2364.

**93)** Blood endothelin-1 levels before and after carotid endoarterectomy for atherosclerotic stenosis. G Properzi, F Francavilla, C. Bellini, P. D'Abriozio, B. Mangiacotti, *Claudio Ferri*, C. Spartera, A. Santucci, S. Francavilla. Atherosclerosis 2001, 154:137-140

**94)** Urinary adrenomedullin is related to ET-1 and salt intake in patients with mild essential hypertension. Salt Sensitivity Group of Italian Society of Hypertension. Cuzzola F, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Cataliotti A, Stancanelli B, Malatino L, Bellanuova I, *Claudio Ferri*, Galletti F, Filigheddu F, Glorioso N, Strazzullo P, Zoccali C. Am J Hypertens 2001, 3:224-230

**95)** The influences of obesity and glycemic control on endothelial activation in patients with type 2 diabetes. W. Bagg, *Claudio Ferri*, G Desideri, G. Gamble, P. Ockleford, G. D. Braadvedt. J Clin Endocrinol Metab 2001, 86(11):5491-5497.

**96)** Prolonged, low dose  $\alpha$ -tocopherol therapy counteracts intercellular cell adhesion molecule-1 activation. G Desideri, G Croce, MC Marinucci, P Masci, M Stati, L Valeri, A. Santucci, *Claudio Ferri*. Clin Chim Acta 2002, 320:5-9

**97)** Patterns of myocardial endothelin-1 expression and outcome after cardiac transplantation. *Claudio Ferri*, G. Properzi, G. Tomassoni, A. Santucci, G. Desideri, A.E. Giuliani, R. Starling, N.B. Ratliff, D.J. Cook, P. McCarthy, Y.B. Young, M.H. Yamani. Circulation 2002, 105:1768-1771.

**98)** Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and von Willebrand factor levels and increase nitric oxide concentrations in hypercholesterolemic patients. G. Desideri, M.C. Marinucci, G. Tomassoni, P. Masci, A. Santucci, *Claudio Ferri*. J Clin Endocrinol Metab 2002, 87:2940-2945.

**99)** Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and von Willebrand factor levels and increase nitric oxide concentrations in hypercholesterolemic patients. G. Desideri, M.C. Marinucci, G. Tomassoni, P. Masci, A. Santucci, *Claudio Ferri*. J Clin Endocrinol Metab 2002, 87:2940-2945.

**100)** Effects of carbon-coated coronary stents on the markers of inflammation, thrombin generation and platelet and endothelial activation. F. Tomai, A. Ghini, *Claudio Ferri*, G. Desideri, F. Versaci, A. Gasparone, L. Altamura, G. Magliano, F. Crea, L. Chiariello. Ital Heart J 2003, 4(1):23-28

**101)** Controlled analysis of blood pressure sensitivity to sodium intake: interactions with hypertension type. S. Hurwitz, N.D.L. Fisher, *Claudio Ferri*, PN. Hopkins, G.H. Williams, N.K. Hollenberg. J Hypertens (previsto per vol 21:943-950 del 2003, con commento editoriale di C. Zoccali)

**102)** Angiotensin II inhibits endothelial cell motility through an AT<sub>1</sub>-dependent oxidant-sensitive decrement of nitric oxide availability. G. Desideri, MC Bravi, M. Tucci, G. Croce, MC Marinucci, E. Alesse, *Claudio Ferri*. Arterioscl Thromb Vasc Biol (previsto per il numero di giugno 2003)

**103)** Effects of obesity and weight loss on soluble CD40L levels. G. Desideri, *Claudio Ferri*. JAMA 2003, 289:1781-1782.

**104)** Endothelial cell activation in men with erectile dysfunction without

cardiovascular risk factors and overt vascular damage. Bocchio M, Desideri G, Scarpelli P, Necozone S, Properzi G, Spartera C, Francavilla F, *Ferri C*, Francavilla S. *J Urol*. 2004 Apr;171(4):1601-4.

**105)** Does nondipping blood pressure profile contribute to vascular inflammation during sleep deprivation? Desideri G, Croce G, *Ferri C*. *J Am Coll Cardiol*. 2004 Oct 6;44(7):1529-30.

**106)** Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Deanfield J, Donald A, *Ferri C*, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ; Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. *J Hypertens*. 2005 Jan;23(1):7-17.

**107)** Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Grassi D, Lippi C, Necozone S, Desideri G, *Ferri C*. *Am J Clin Nutr*. 2005 Mar;81(3):611-4.

**108)** Early activation of vascular endothelial cells and platelets in obese children. Desideri G, De Simone M, Iughetti L, Rosato T, Iezzi ML, Marinucci MC, Cofini V, Croce G, Passacquale G, Necozone S, *Ferri C*. *J Clin Endocrinol Metab*. 2005 Jun;90(6):3145-52.

**109)** Treatment of hypertension and adherence to treatment guidelines in clinical practice: an Italian study. Malacco E, *Ferri C*, Grandi AM, Kilama MO, Sogliani AG, Vigna L. *Adv Ther*. 2005 Mar-Apr;22(2):96-106. Endothelial activation. Sliding door to atherosclerosis. Desideri G, *Ferri C*. *Curr Pharm Des*. 2005;11(17):2163-75.

**110)** Endothelial activation. Sliding door to atherosclerosis. Desideri G, *Ferri C*. *Curr Pharm Des*. 2005;11(17):2163-75.

**111)** Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Grassi D, Necozone S, Lippi C, Croce G, Valeri L, Pasqualetti P, Desideri G, Blumberg JB, *Ferri C*. *Hypertension*. 2005 Aug;46(2):398-405.

**112)** Nonpharmacological treatment of hypercholesterolemia increases circulating endothelial progenitor cell population in adults. Croce G, Passacquale G, Necozone S, *Ferri C*, Desideri G. *Arterioscler Thromb Vasc Biol*. 2006 May;26(5):e38-9.

**113)** Renal damage in primary aldosteronism: results of the PAPY Study. Rossi GP, Bernini G, Desideri G, Fabris B, *Ferri C*, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F; PAPY Study Participants. *Hypertension*. 2006 Aug;48(2):232-8.

**114)** Cocoa beans, endothelial function and aging: an unexpected friendship? *Ferri C*, Grassi D, Grassi G. *J Hypertens*. 2006 Aug;24(8):1471-4.

**115)** Limitations and discrepancies of transthoracic and transoesophageal echocardiography compared with surgical findings in patients submitted to surgery for complications of infective endocarditis. Cicioni C, Di Luzio V, Di Emidio L, De Remigis F, Fragassi G, Gregorini R, Mazzola A, Papanoni S, Prospero F, *Ferri C*. *J Cardiovasc Med (Hagerstown)*. 2006 Sep;7(9):660-6.

**116)** A prospective study of the prevalence of primary aldosteronism in 1,125

hypertensive patients. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, *Ferri C*, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. *J Am Coll Cardiol*. 2006 Dec 5;48(11):2293-300.

**117)** Enhanced plasma soluble CD40 ligand levels in essential hypertensive patients with blunted nocturnal blood pressure decrease. Desideri G, Cipollone F, Valeri L, Grassi D, Necozone S, Croce G, Passacquale G, Garofalo A, Lippi C, Mezzetti A, *Ferri C*. *Am J Hypertens*. 2007 Jan;20(1):70-6.

**118)** Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, *Ferri C*, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F; PAPY Study Investigators. *J Hypertens*. 2007 Jul;25(7):1433-42.

**119)** C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. *Ferri C*, Croce G, Cofini V, De Berardinis G, Grassi D, Casale R, Properzi G, Desideri G. *Curr Pharm Des*. 2007;13(16):1631-45.

**120)** COX-2: friend or foe? Iezzi A, *Ferri C*, Mezzetti A, Cipollone F. *Curr Pharm Des*. 2007;13(16):1715-21.

**121)** Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, *Ferri C*, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F; Primary Aldosteronism Prevalence in Italy Study Investigators. *Hypertension*. 2007 Aug;50(2):424-31.

**122)** Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible pathogenetic role. Desideri G, Cipollone F, Necozone S, Marini C, Lechiara MC, Taglieri G, Zuliani G, Fellin R, Mezzetti A, di Orio F, *Ferri C*. *Neurobiol Aging*. 2008 Mar;29(3):348-56.

**123)** Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Bocchio M, Pelliccione F, Passacquale G, Mihalca R, Necozone S, Desideri G, Francavilla F, *Ferri C*, Francavilla S. *Atherosclerosis*. 2008 Jan;196(1):313-9.

**124)** Nifedipine improves the migratory ability of circulating endothelial progenitor cells depending on manganese superoxide dismutase upregulation. Passacquale G, Desideri G, Croce G, Murgio S, Mancarelli MM, Zazzeroni F, Alesse E, *Ferri C*. *J Hypertens*. 2008 Apr;26(4):737-46.

**125)** Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, *Ferri C*, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F; Primary Aldosteronism Prevalence in Hypertension Study Investigators. *J Clin Endocrinol Metab*. 2008 Jul;93(7):2566-71.

**126)** Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. *Ferri C*, Croce G, Desideri G. *Adv Ther*. 2008 Apr;25(4):300-20.

- 127)** Tea, flavonoids, and nitric oxide-mediated vascular reactivity. Grassi D, Aggio A, Onori L, Croce G, Tiberti S, *Ferri C*, Ferri L, Desideri G. *J Nutr*. 2008 Aug;138(8).
- 128)** Morphology of atherosclerotic plaque: its feature by imaging study. Passacuale G, Tiberti S, *Ferri C*, Desideri G. *Curr Pharm Des*. 2008;14(18):1753-60.
- 129)** Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. Grassi D, Desideri G, Necozone S, Lippi C, Casale R, Properzi G, Blumberg JB, *Ferri C*. *J Nutr*. 2008 Sep;138(9):1671-6.
- 130)** Electrophysiological effects of short-term antihypertensive therapy. *Ferri C*, Pasqualetti P, Tiberti S, Grassi D. *Expert Rev Cardiovasc Ther*. 2008 Nov;6(10).
- 131)** Cardiovascular risk and cardiometabolic protection: role of glitazones. Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, *Ferri C*. *J Nephrol*. 2008 Nov-Dec;21(6):826-35.
- 132)** Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S, Necozone S, Di Orio F, *Ferri C*. *Mediators Inflamm*. 2008;2008:305087.
- 133)** Practical solutions to the challenges of uncontrolled hypertension: a white paper. Redon J, Brunner HR, *Ferri C*, Hilgers KF, Kolloch R, van Montfrans G. *J Hypertens Suppl*. 2008 Dec;26(4):S1-14.
- 134)** Chocolate, lifestyle, and health. Visioli F, Bernaert H, Corti R, *Ferri C*, Heptinstall S, Molinari E, Poli A, Serafini M, Smit HJ, Vinson JA, Violi F, Paoletti R. *Crit Rev Food Sci Nutr*. 2009 Apr;49(4):299-312.
- 135)** Black tea consumption dose-dependently improves flow-mediated dilation in healthy males. Grassi D, Mulder TP, Draijer R, Desideri G, Molhuizen HO, *Ferri C*. *J Hypertens*. 2009 Apr;27(4):774-81.
- 136)** Enhanced proatherogenic inflammation after recombinant human TSH administration in patients monitored for thyroid cancer remnant. Desideri G, Bocale R, Milardi D, Ghiadoni L, Grassi D, Necozone S, Taddei S, di Orio F, Pontecorvi A, *Ferri C*. *Clin Endocrinol (Oxf)*. 2009 Sep;71(3):429-33.
- 137)** Flavonoids, vascular function and cardiovascular protection. Grassi D, Desideri G, Croce G, Tiberti S, Aggio A, *Ferri C*. *Curr Pharm Des*. 2009;15(10):1072-84.
- 138)** Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Rossi GP, Seccia TM, Palumbo G, Belfiore A, Bernini G, Caridi G, Desideri G, Fabris B, *Ferri C*, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F; Primary Aldosteronism in the Prevalence in hYpertension (PAPY) Study Investigators. *Hypertension*. 2010 Jan;55(1):83-9.
- 139)** Pelvic floor rehabilitation for continence recovery after radical prostatectomy: role of a personal training re-educational program. Marchiori D, Bertaccini A, Manfredi F, *Ferri C*, Martorana G. *Anticancer Res*. 2010 Feb;30(2):553-6.
- 140)** In uno omnia: anti-thrombotic agents in challenging comorbidities. Pistoia F, *Ferri C*, Desideri G, Rosano G, Sarà M. *Brain Inj*. 2010;24(5):792-6.

- 141)** Antioxidants and beneficial microvascular effects: is this the remedy? *Ferri C, Grassi D.* Hypertension. 2010 Jun;55(6):1310-1.
- 142)** Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). *Ambrosioni E, Bombelli M, Cerasola G, Cipollone F, Ferri C, Grazioli I, Leprotti C, Mancia G, Melzi G, Mugellini A, Mulè G, Palasciano G, Salvetti A, Trimarco B.* Adv Ther. 2010 Jun;27(6):365-80.
- 143)** Flavonoids: antioxidants against atherosclerosis. *Grassi D, Desideri G, Ferri C.* Nutrients. 2010 Aug;2(8):889-902.
- 144)** The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. *Rossi GP, Barisa M, Belfiore A, Desideri G, Ferri C, Letizia C, Maccario M, Morganti A, Palumbo G, Patalano A, Roman E, Seccia TM, Pessina AC, Mantero F; PAPY study Investigators.* J Hypertens. 2010 Sep;28(9):1892-9.
- 145)** Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. *Scholze J, Alegria E, Ferri C, Langham S, Stevens W, Jeffries D, Uhl-Hochgraeber K.* BMC Public Health. 2010 Sep 2;10:529.
- 146)** Blood pressure and cardiovascular risk: what about cocoa and chocolate? *Grassi D, Desideri G, Ferri C.* Arch Biochem Biophys. 2010 Sep 1;501(1):112-5.
- 147)** Changes in 24-hour ambulatory blood pressure monitoring during the 2009 earthquake at L'Aquila. *Petrazzi L, Striuli R, Polidoro L, Properzi G, Casale R, Pasqualetti P, Desideri G, Ferri C, Parati G.* Am J Med. 2010 Oct;123(10):e1-3.
- 148)** Oxidative stress and endothelial dysfunction: say NO to cigarette smoking! *Grassi D, Desideri G, Ferri L, Aggio A, Tiberti S, Ferri C.* Curr Pharm Des. 2010;16(23):2539-50.
- 149)** The role of Doppler ultrasound in the diagnosis of vasculogenic impotence. *Debora M, Daniele A, Alessandro B, Ferri C, Giuseppe M.* Arch Ital Urol Androl. 2010 Dec;82(4):159-63.
- 150)** Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. *Wille E, Scholze J, Alegria E, Ferri C, Langham S, Stevens W, Jeffries D, Uhl-Hochgraeber K.* Eur J Health Econ. 2011 Jun;12(3):205-18.
- 151)** Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study). *Mancia G, Rosei EA, Ambrosioni E, Avino F, Carolei A, Daccò M, Di Giacomo G, Ferri C, Grazioli I, Melzi G, Nappi G, Pinessi L, Sandrini G, Trimarco B, Zanchin G; MIRACLES Study Group.* J Hypertens. 2011 Feb;29(2):309-18.
- 152)** Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. *Redon J, Erdine S, Böhm M, Ferri C, Kolloch R, Kreutz R, Laurent S, Persu A, Schmieder RE; SHARE Steering Committee.* J Hypertens. 2011 Aug;29(8):1633-40.
- 153)** Cardiovascular risk and endothelial dysfunction: the preferential route for atherosclerosis. *Grassi D, Desideri G, Ferri C.* Curr Pharm Biotechnol. 2011



Sep;12(9):1343-53.

**154)** Hidden sodium in Mediterranean food. *Ferri C, Grassi D.* *J Hypertens.* 2011 Oct;29(10):2041-2.

**155)** Aortic stiffness, blood pressure and renal dysfunction. *Grassi D, Ferri C.* *Intern Emerg Med.* 2011 Oct;6 Suppl 1:111-4.

**156)** Cognitive decline as a consequence of essential hypertension. *Grassi D, Ferri L, Cheli P, Di Giosia P, Ferri C.* *Curr Pharm Des.* 2011;17(28):3032-8.

**157)** The history of primary hyperaldosteronism with simultaneous hypercortisolism. *Ferri C, Grassi D.* *J Hypertens.* 2012 Feb;30(2):432-3.

**158)** Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. *Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, Ferrucci A, Mancina G, Morganti A, Pontremoli R, Trimarco B, Zanchetti A, Volpe M.* *J Hypertens.* 2012 Jun;30(6):1065-74.

**159)** Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive hypertension. *Williams JS, Chamarthi B, Goodarzi MO, Pojoga LH, Sun B, Garza AE, Raby BA, Adler GK, Hopkins PN, Brown NJ, Jeunemaitre X, Ferri C, Fang R, Leonor T, Cui J, Guo X, Taylor KD, Ida Chen YD, Xiang A, Raffel LJ, Buchanan TA, Rotter JJ, Williams GH, Shi Y.* *Am J Hypertens.* 2012 Jul;25(7):812-7.

**160)** The Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS) study: rationale and study design. *Rossi GP, Seccia TM, Miotto D, Zucchetta P, Cecchin D, Calò L, Puato M, Motta R, Caielli P, Vincenzi M, Ramondo G, Taddei S, Ferri C, Letizia C, Borghi C, Morganti A, Pessina AC; METRAS Investigators.* *J Hum Hypertens.* 2012 Aug;26(8):507-16.

**161)** Different polymorphisms of the mineralocorticoid receptor gene are associated with either glucocorticoid or mineralocorticoid levels in hypertension. *Sun B, Chamarthi B, Williams JS, Krug AW, Lasky-Su J, Raby BA, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH.* *J Clin Endocrinol Metab.* 2012 Sep;97(9):E1825-9.

**162)** Protective effects of flavanol-rich dark chocolate on endothelial function and wave reflection during acute hyperglycemia. *Grassi D, Desideri G, Necozone S, Ruggieri F, Blumberg JB, Stornello M, Ferri C.* *Hypertension.* 2012 Sep;60(3):827-32.

**163)** Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. *Desideri G, Kwik-Urbe C, Grassi D, Necozone S, Ghiadoni L, Mastroiacovo D, Raffaele A, Ferri L, Bocale R, Lechiara MC, Marini C, Ferri C.* *Hypertension.* 2012 Sep;60(3):794-801.

**164)** Nonmodulation as the mechanism for salt sensitivity of blood pressure in individuals with hypertension and type 2 diabetes mellitus. *Underwood PC, Chamarthi B, Williams JS, Vaidya A, Garg R, Adler GK, Grotzke MP, Staskus G, Wadwekar D, Hopkins PN, Ferri C, McCall A, McClain D, Williams GH.* *J Clin Endocrinol Metab.* 2012 Oct;97(10):3775-82.

**165)** [Renal denervation for the treatment of resistant hypertension: definition, patient selection and description of the procedure. 2012 Position paper of the Italian Society of Hypertension]. *Volpe M, Agabiti-Rosei E, Ambrosioni E, Cottone S, Cuspidi C,*

Borghi C, De Luca N, Fallo F, *Ferri C*, Mancia G, Morganti A, Muiesan ML, Sarzani R, Sechi L, Tocci G, Virdis A; Società Italiana dell'Ipertensione Arteriosa. *G Ital Cardiol* (Rome). 2012 Dec;13(12):846-52.

**166)** Strategies for improving blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. 2012 Position paper of the Italian Society of Hypertension].Volpe M, Ambrosioni E, Borghi C, Cottone S, Cuspidi C, De Luca N, Fallo F, *Ferri C*, Morganti A, Muiesan ML, Sarzani R, Sechi L, Virdis A, Tocci G, Agabiti-Rosei E, Trimarco B, Filippi A, Mancia G; Società Italiana dell'Ipertensione Arteriosa. *G Ital Cardiol* (Rome). 2012 Dec;13(12):853-60.

**167)** Renal artery denervation for treating resistant hypertension : definition of the disease, patient selection and description of the procedure.Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, De Luca N, Fallo F, *Ferri C*, Mancia G, Morganti A, Muiesan ML, Sarzani R, Sechi L, Tocci G, Virdis A; Italian Society of Hypertension. *High Blood Press Cardiovasc Prev*. 2012 Dec;19(4):237-44.

**168)** Endothelium/nitric oxide mechanism mediates vasorelaxation and counteracts vasoconstriction induced by low concentration of flavanols.Aggio A, Grassi D, Onori E, D'Alessandro A, Masedu F, Valenti M, *Ferri C*. *Eur J Nutr*. 2013 Feb;52(1):263-72.

**169)** 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy.Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, De Luca N, Fallo F, *Ferri C*, Morganti A, Muiesan ML, Sarzani R, Sechi L, Virdis A, Tocci G, Trimarco B, Filippi A, Mancia G; Italian Society of Hypertension. *High Blood Press Cardiovasc Prev*. 2013 Mar;20(1):45-52.

**170)** Renin-angiotensin-aldosterone system blockade is safe and effective in elderly hypertensive patients with and without impaired renal function.Ferri C, Ferri L.*High Blood Press Cardiovasc Prev*. 2012 Dec;19(4):197-8.

**171)** Abnormal aldosterone physiology and cardiometabolic risk factors.Vaidya A, Underwood PC, Hopkins PN, Jeunemaitre X, *Ferri C*, Williams GH, Adler GK. *Hypertension*. 2013 Apr;61(4):886-93.

**172)** Long-term blood pressure changes induced by the 2009 L'Aquila earthquake: assessment by 24 h ambulatory monitoring.Giorgini P, Striuli R, Petrarca M, Petrazzi L, Pasqualetti P, Properzi G, Desideri G, Omboni S, Parati G, *Ferri C*. *Hypertens Res*. 2013 Sep;36(9):795-8.

**173)** Clinical management of hypertension in pregnancy. Practical recommendations from the Italian Society of Hypertension (SIIA). [corrected].Borghi C, *Ferri C*, Sechi L; Italian Society of Hypertension. *High Blood Press Cardiovasc Prev*. 2013 Sep;20(3):123-7.

**174)** Are physicians underestimating the challenges of hypertension management?Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey. Erdine S, Redon J, Böhm M, *Ferri C*, Kolloch R, Kreutz R, Laurent S, Persu A, Schmieder RE; SHARE Steering Committee. *Eur J Prev Cardiol*. 2013 Oct;20(5):786-92.

**175)** Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis. Marampon F, Gravina GL, Scarsella L, Festuccia C, Lovat F, Ciccarelli C, Zani BM, Polidoro L, Grassi D, Desideri G, Evangelista S, *Ferri C*. *J Hypertens*. 2013;31(10):1972-83.

- 176)** Cocoa powder triggers neuroprotective and preventive effects in a human Alzheimer's disease model by modulating BDNF signaling pathway. Cimini A, Gentile R, D'Angelo B, Benedetti E, Cristiano L, Avantiaggiati ML, Giordano A, *Ferri C*, Desideri G. *J Cell Biochem*. 2013 Oct;114(10):2209-20.
- 177)** Protective effects of dark chocolate on endothelial function and diabetes. Grassi D, Desideri G, *Ferri C*. *Curr Opin Clin Nutr Metab Care*. 2013 Nov;16(6):662-8.
- 178)** Tea, flavonoids, and cardiovascular health: endothelial protection. Grassi D, Desideri G, Di Giosia P, De Feo M, Fellini E, Cheli P, *Ferri L*, *Ferri C*. *Am J Clin Nutr*. 2013 Dec;98(6 Suppl):1660S-1666S.
- 179)** Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Grassi D, *Ferri L*, Desideri G, Di Giosia P, Cheli P, Del Pinto R, Properzi G, *Ferri C*. *Curr Pharm Des*. 2013;19(13):2432-8.
- 180)** Hyperuricemia and cardiovascular risk. Grassi D, Desideri G, Di Giacomantonio AV, Di Giosia P, *Ferri C*. *High Blood Press Cardiovasc Prev*. 2014 Feb 20.
- 181)** National survey on excellence centers and reference centers for hypertension diagnosis and treatment: geographical distribution, medical facilities and diagnostic opportunities. Tocci G, De Luca N, Sarzani R, Ambrosioni E, Borghi C, Cottone S, Cuspidi C, Fallo F, *Ferri C*, Morganti A, Muiesan ML, Sechi L, Virdis A, Mancia G, Volpe M. *High Blood Press Cardiovasc Prev*. 2014 Mar;21(1):29-36.
- 182)** New Insight into Urate-Related Mechanism of Cardiovascular Damage. Grassi D, Desideri G, *Ferri C*. *Curr Pharm Des*. 2014 Apr 16.
- 183)** Therapeutic Approaches to Chronic Hyperuricemia and Gout. Grassi D, Pontremoli R, Bocale R, *Ferri C*, Desideri G. *High Blood Press Cardiovasc Prev*. 2014 Apr 3.
- 184)** Serum uric acid levels and metabolic syndrome. Ciarla S, Struglia M, Giorgini P, Striuli R, Necozone S, Properzi G, *Ferri C*. *Arch Physiol Biochem*. 2014 Jun 10:1-4.
- 185)** Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk. Brown JM, Underwood PC, *Ferri C*, Hopkins PN, Williams GH, Adler GK, Vaidya A. *Hypertension*. 2014 Jun;63(6):1205-11.
- 186)** Galletti F, Agabiti-Rosei E, Bernini G, Boero R, Desideri G, Fallo F, Mallamaci F, Morganti A, Castellano M, Nazzaro P, Trimarco B, Strazzullo P; MINISAL-GIRCSI Program Study Group. Excess dietary sodium and inadequate potassium intake by hypertensive patients in Italy: results of the MINISAL-SIIA study program. *J Hypertens*. 2014;32(1):48-56.
- 187)** Garza AE, Rariy CM, Sun B, Williams JS, Lasky-Su J, Baudrand R, Yao T, Moize B, Hafiz WM, Romero JR, Adler GK, *Ferri C*, Hopkins PN, Pojoga LH, Williams GH. Variants in striatin gene are associated with salt-sensitive blood pressure in mice and humans. *Hypertension*. 2015;65(1):211-7.
- 188)** Grassi D, Desideri G, Necozone S, di Giosia P, Barnabei R, Allegaert L, Bernaert H, *Ferri C*. Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals. *J Hypertens*. 2015;33(2):294-303.

- 189)** Del Pinto R, Pietropaoli D, Chandar AK, *Ferri C*, Cominelli F. Association Between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-analysis. *Inflamm Bowel Dis*. 2015;21(11):2708-17.
- 190)** Ciarla S, Giorgini P, Struglia M, Striuli R, Necozone S, Desideri G, Properzi G, *Ferri C*. Associations between low levels of serum uric acid and cardiometabolic parameters. *Arch Physiol Biochem*. 2015;121(4):139-43.
- 191)** Giorgini P, Rubenfire M, Das R, Gracik T, Wang L, Morishita M, Bard RL, Jackson EA, Fitzner CA, *Ferri C*, Brook RD. Particulate matter air pollution and ambient temperature: opposing effects on blood pressure in high-risk cardiac patients. *J Hypertens*. 2015;33(10):2032-8.
- 192)** Grassi D, Desideri G, Mai F, Martella L, De Feo M, Soddu D, Fellini E, Veneri M, Stamerra CA, *Ferri C*. Cocoa, glucose tolerance, and insulin signaling: cardiometabolic protection. *J Agric Food Chem*. 2015;63(45):9919-26.
- 193)** *Ferri C*, Desideri G, Ferri L, Proietti I, Di Agostino S, Martella L, Mai F, Di Giosia P, Grassi D. Cocoa, blood pressure, and cardiovascular health. *J Agric Food Chem*. 2015;63(45):9901-9.
- 194)** Ghiadoni L, Bruno RM, Cartoni G, Stea F, Magagna A, Virdis A, Grassi D, *Ferri C*, Taddei S. Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome. *Vascul Pharmacol*. 2015 Jun 10.
- 195)** Giorgini P, Rubenfire M, Das R, Gracik T, Wang L, Morishita M, Bard RL, Jackson EA, Fitzner CA, *Ferri C*, Brook RD. Higher fine particulate matter and temperature levels impair exercise capacity in cardiac patients. *Heart*. 2015;101(16):1293-301.
- 196)** Giorgini P, Rubenfire M, Bard RL, Jackson EA, *Ferri C*, Brook RD. Air Pollution and Exercise: a review of the cardiovascular implications for healthcare professionals . *J Cardiopulm Rehabil Prev*. 2016, 36(2):84-95.
- 197)** Martocchia A, Stefanelli M, Falaschi GM, Toussan L, *Ferri C*, Falaschi P. Recent advances in the role of cortisol and metabolic syndrome in age-related degenerative diseases. *Aging Clin Exp Res*. 2016;28(1):17-23.
- 198)** Mastroiacovo D, Kwik-Urbe C, Grassi D, Necozone S, Raffaele A, Pistacchio L, Righetti R, Bocale R, Lechiara MC, Marini C, *Ferri C*, Desideri G. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study--a randomized controlled trial. *Am J Clin Nutr*. 2015;101(3):538-48.
- 199)** Giorgini P, Di Giosia P, Grassi D, Rubenfire M, Brook RD, *Ferri C*. Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature. *Curr Pharm Des*. 2016;22(1):28-51.
- 200)** Grassi D, *Ferri C*, Desideri G. Brain Protection and Cognitive Function: Cocoa Flavonoids as Nutraceuticals. *Curr Pharm Des*. 2016;22(2):145-51.
- 201)** Tocci G, Ferrucci A, Pontremoli R, *Ferri C*, Rosei EA, Morganti A, Trimarco B, Mancia G, Borghi C, Volpe M. Blood pressure levels and control in Italy:

comprehensive analysis of clinical data from 2000-2005 and 2005-2011 hypertension surveys. *J Hum Hypertens*. 2015;29(11):696-701.

**202)** Grassi D, Draijer R, Desideri G, Mulder T, *Ferri C*. Black tea lowers blood pressure and wave reflections in fasted and postprandial conditions in hypertensive patients: a randomised study. *Nutrients*. 2015;7(2):1037-51.

**203)** *Ferri C*. Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease. *High Blood Press Cardiovasc Prev*. 2015;22(2):103-11.

**204)** Di Giosia P, Giorgini P, *Ferri C*. Is labor-onset hypertension a novel category among hypertensive disorders of pregnancy associated with adverse events in high-risk subjects? Lights and shadows. *Hypertens Res*. 2016; 39(6):401-3

**205)** Sahebkar A, Simental-Mendía LE, Giorgini P, *Ferri C*, Grassi D. Lipid profile changes after pomegranate consumption: A systematic review and meta-analysis of randomized controlled trials. *Phytomedicine*. 2016; 23(11):1103-12.

**206)** Sahebkar A, Di Giosia P, Stamerra CA, Grassi D, Pedone C, Ferretti G, Bacchetti T, *Ferri C*, Giorgini P. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: A Meta-Analysis of 16 Randomized Controlled Treatment Arms. *Br J Clin Pharmacol*. 2016; 81(6):1175-90

**207)** Giorgini P, Grassi D, Di Giosia P, *Ferri C*. Exercise training improves cardiopulmonary and endothelial function in women with breast cancer: findings from the Diana-5 study. *Intern Emerg Med*. 2016;11(2):171-3.

**208)** Giorgini P, Di Giosia P, Ferri L, *Ferri C*. Cardiovascular events in patients with the chronic obstructive bronchopulmonary disease. *J Cardiovasc Med*. 2016. [Epub ahead of print]

**209)** Baudrand R, Gupta N, Garza AE, Vaidya A, Leopold JA, Hopkins PN, Jeunemaitre X, *Ferri C*, Romero JR, Williams J, Loscalzo J, Adler GK, Williams GH, Pojoga LH. Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis. *J Am Heart Assoc*. 2016;5(10).

**210)** Rozza F, Trimarco V, Izzo R, Grassi D, *Ferri C*. Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study. *High Blood Press Cardiovasc Prev*. 2016; 23(4):381-386

**211)** Sahebkar A, Giorgini P, Ludovici V, Pedone C, Ferretti G, Bacchetti T, Grassi D, Di Giosia P, *Ferri C*. Impact of statin therapy on plasma resistin and visfatin concentrations: A systematic review and meta-analysis of controlled clinical trials. *Pharmacol Res*. 2016;111:827-37

**212)** Grassi D, Socci V, Tempesta D, *Ferri C*, De Gennaro L, Desideri G, Ferrara M. Flavanol-rich chocolate acutely improves arterial function and working memory performance counteracting the effects of sleep deprivation in healthy individuals. *J Hypertens*. 2016;34(7):1298-308

**213)** Tocci G, Muiesan ML, Parati G, Agabiti Rosei E, *Ferri C*, Virdis A, Pontremoli R, Mancia G, Borghi C, Volpe M; Working Group of the Italian Society of

Hypertension (SIIA) and SIIA Foundation. Trends in Prevalence, Awareness, Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World Hypertension Day in Italy. *J Clin Hypertens* 2016;18(6):551-6.

**214)** Galletti F, Barbato A; MINISAL-SIIA Study Group. Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program. *J Hum Hypertens*. 2016;30(11):703-708.

**215)** Redon J, Pichler G; Missed Dose Study Group. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. *J Hypertens*. 2016;34(2):359-67.

**216)** Grassi D, Draijer R, Schalkwijk C, Desideri G, D'Angeli A, Francavilla S, Mulder T, *Ferri C*. Black Tea Increases Circulating Endothelial Progenitor Cells and Improves Flow Mediated Dilatation Counteracting Deleterious Effects from a Fat Load in Hypertensive Patients: A Randomized Controlled Study. *Nutrients*. 2016 16;8(11).

**217)** Petrarca M, Scipioni R, Di Giosia P, Giorgini P, Ferri C. A case of brain calcifications in postsurgical hypoparathyroidism. *Intern Emerg Med*. 2017;12(1):113-115.

**218)** Desideri G, Gentile R, Antonosante A, Benedetti E, Grassi D, Cristiano L, Manocchio A, Selli S, Ippoliti R, *Ferri C*, Borghi C, Giordano A, Cimini A. Uric Acid Amplifies A $\beta$  Amyloid Effects Involved in the Cognitive Dysfunction/Dementia: Evidences From an Experimental Model In Vitro. *J Cell Physiol*. 2017; 232(5):1069-1078

**219)** Giorgini P, Di Giosia P, Ferri L, Ferri C. Cardiovascular events in patients with chronic obstructive bronchopulmonary disease. *J Cardiovasc Med* 2017; 18 Suppl 1:e23-e29.

**220)** Sahebkar A, Ferri C, Giorgini P, Bo S, Nachtigal P, Grassi D. Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials. *Pharmacol Res*. 2017;115:149-161.

**221)** Giorgini P, Sahebkar A, Stamerra CA, Raparelli V, Petrarca M, Grassi D, *Ferri C*, Di Giosia P. Comparison of Clinical Outcomes Between Genders Following Antihypertensive Therapy: A Meta-Analysis. *Curr Med Chem*. 2017;24(24):2639-2649.

**222)** Ferri C, Ferri L, Desideri G. Management of Hypertension in the Elderly and Frail Elderly. *High Blood Press Cardiovasc Prev*. 2017;24(1):1-11.

**223)** Giorgini P, Di Giosia P, Petrarca M, Lattanzio F, Stamerra CA, Ferri C. Climate Changes and Human Health: A Review of the Effect of Environmental Stressors on Cardiovascular Diseases Across Epidemiology and Biological Mechanisms. *Curr Pharm Des*. 2017;23(22):3247-3261.

**224)** Maiolino G, Rossitto G, Bisogni V, Cesari M, Seccia TM, Plebani M, Rossi GP; PAPY Study Investigators. Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study. *J Am Heart Assoc*. 2017;21;6(5).

- 225)** Cardiovascular risk and hypertension control in Italy. Data from the 2015 World Hypertension Day. Torlasco C, Faini A, Makil E, *Ferri C*, Borghi C, Veglio F, Desideri G, Agabiti Rosei E, Ghiadoni L, Pauletto P, Pontremoli R, Stornello M, Tocci G, Galletti F, Trimarco B, Parati G; Council of the Italian Society of Hypertension. *Int J Cardiol.* 2017;243:529-532.
- 226)** Ludovici V, Barthelmes J, Nägele MP, Enseleit F, *Ferri C*, Flammer AJ, Ruschitzka F, Sudano I. Cocoa, Blood Pressure, and Vascular Function. *Front Nutr.* 2017;4:36.
- 227)** *Ferri C*. The problem of cardio-renal diseases in patients with gout. *Curr Med Res Opin.* 2017;33(sup3):9-13.
- 228)** Castelli V, Grassi D, Bocale R, d'Angelo M, Antonosante A, Cimini A, *Ferri C*, Desideri G. Diet and Brain Health: Which Role for Polyphenols? *Curr Pharm Des.* 2017 Dec 12.
- 229)** Stamerra CA, Di Giosia P, Giorgini P, De Feo M, Grassi D, *Ferri C*, Sahebkar A. Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence. *J Neurosci Res.* 2018;96(5):762-764.
- 230)** Cervelli N, Tocci G, *Ferri C*. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? *High Blood Press Cardiovasc Prev.* 2018 Jan 5.
- 231)** *Ferri C*. Diuretics (chapter). *Encyclopedia of Endocrine Diseases*, 2nd Edition. MRW - Elsevier Limited. In press.
- 232)** Pietropaoli D, Del Pinto R, *Ferri C*, Wright JT Jr, Giannoni M, Ortu E, Monaco A. Poor Oral Health and Blood Pressure Control Among US Hypertensive Adults: Results From the National Health and Nutrition Examination Survey 2009 to 2014 Hypertension. 2018;72(6):1365-1373
- 233)** Duro G, Zizzo C, Cammarata G, Burlina A, Burlina A, Polo G, Scalia S, Oliveri R, Sciarrino S, Francofonte D, Alessandro R, Pisani A, Palladino G, Napoletano R, Tenuta M, Masarone D, Limongelli G, Riccio E, Frustaci A, Chimenti C, *Ferri C*, Pieruzzi F, Pieroni M, Spada M, Castana C, Caserta M, Monte I, Rodolico MS, Feriozzi S, Battaglia Y, Amico L, Losi MA, Autore C, Lombardi M, Zoccali C, Testa A, Postorino M, Mignani R, Zachara E, Giordano A, Colomba P. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease? *Int J Mol Sci.* 2018 Nov 23;19(12).
- 234)** Del Pinto R, *Ferri C*. Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives. *Int J Mol Sci.* 2018;19(12).
- 235)** Del Pinto R, *Ferri C*. Hypertension Management at Older Age: An Update. *High Blood Press Cardiovasc Prev.* 2018 Nov 22.
- 236)** Bringhen S, Milan A, *Ferri C*, Wäsch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M; European Hematology Association, the European Myeloma Network and the Italian Society of Arterial Hypertension. Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). *Haematologica.* 2018;103(9):1422-1432.

- 237)** Crosta F, Occhiuzzi U, Passalacqua G, Occhiuzzi E, Cimini A, Grassi D, *Ferri C*, Marini C, Borghi C, Desideri G. Association Between the Serum Uric Acid Levels and Lacunar Infarcts in the Elderly. *J Mol Neurosci*. 2018;65(3):385-390.
- 238)** Del Pinto R, *Ferri C*, Borghi C. Letter Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". *Circulation*. 2018;137(24):2654-2655.
- 239)** Del Pinto R, Pietropaoli D, *Ferri C*. Diastolic blood pressure and risk profile in renal and cardiovascular diseases. Results from the SPRINT trial. *J Am Soc Hypertens*. 2018;12(7):513-523.e3.
- 240)** Del Pinto R, Pietropaoli D, Russomando U, Evangelista P, *Ferri C*. Health status of Afro-Asian refugees in an Italian urban area: a cross-sectional monocentric study. *Public Health*. 2018;158:176-182.
- 241)** Di Giosia P, Giorgini P, *Ferri C*. Considerations on stroke in atrial fibrillation despite anticoagulation. *J Cardiovasc Med (Hagerstown)*. 2018;19 Suppl 1:e54-e57. doi: 10.2459/JCM.0000000000000602. No abstract available.
- 242)** Di Giosia P, Giorgini P, Stamerra CA, Petrarca M, *Ferri C*, Sahebkar A. Gender Differences in Epidemiology, Pathophysiology, and Treatment of Hypertension. *Curr Atheroscler Rep*. 2018;20(3):13.
- 243)** Desideri G, Viridis A, Casiglia E, Borghi C; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension. Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study. *High Blood Press Cardiovasc Prev*. 2018;25(2):197-202.
- 244)** Del Pinto R, *Ferri C*. Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives. *Int J Mol Sci*. 2018;19(12).
- 245)** Del Pinto R, *Ferri C*. Hypertension Management at Older Age: An Update. *High Blood Press Cardiovasc Prev*. 2019 Feb;26(1):27-36. doi: 10.1007/s40292-018-0290-z. Epub 2018 Nov 22.
- 246)** Pietropaoli D, Del Pinto R, *Ferri C*, Wright JT Jr, Giannoni M, Ortu E, Monaco A. Poor Oral Health and Blood Pressure Control Among US Hypertensive Adults: Results From the National Health and Nutrition Examination Survey 2009 to 2014 Hypertension. 2018;72(6):1365-1373.
- 247)** Duro G, Zizzo C, Cammarata G, Burlina A, Burlina A, Polo G, Scalia S, Oliveri R, Sciarrino S, Francofonte D, Alessandro R, Pisani A, Palladino G, Napoletano R, Tenuta M, Masarone D, Limongelli G, Riccio E, Frustaci A, Chimenti C, *Ferri C*, Pieruzzi F, Pieroni M, Spada M, Castana C, Caserta M, Monte I, Rodolico MS, Feriozzi S, Battaglia Y, Amico L, Losi MA, Autore C, Lombardi M, Zoccali C, Testa A, Postorino M, Mignani R, Zachara E, Giordano A, Colomba P. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease? *Int J Mol Sci*. 2018;19(12).
- 248)** Bringham S, Milan A, D'Agostino M, *Ferri C*, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner H, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M. Prevention, monitoring and treatment of cardiovascular



adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. *J Intern Med.* 2019 Feb 6.

**249)** Cicero AFG, Grassi D, Tocci G, Galletti F, Borghi C, *Ferri C.* Nutrients and Nutraceuticals for the Management of High Normal Blood Pressure: An Evidence-Based Consensus Document. *High Blood Press Cardiovasc Prev.* 2019;26(1):9-25.

**250)** Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors. *High Blood Press Cardiovasc Prev.* 2019;26(3):199-207.

**251)** Del Pinto R, Pagliacci S, De Feo M, Grassi D, Ferri C; Italian Society of Hypertension and Federfarma. Prevalence of hypertension and associated cardiovascular risk factors among pharmacies customers: an Italian nationwide epidemiological survey. *Eur J Prev Cardiol.* 2019 May 22:2047487319851301.

**252)** Pietropaoli D, Del Pinto R, Ferri C, Ortu E, Monaco A. Definition of hypertension-associated oral pathogens in NHANES. *J Periodontol.* 2019 May 15.

**253)** Is circulating endothelin evaluation useful for clinicians? Ferri C, Desideri G. *Intern Emerg Med.* 2019 May 10.

**254)** Torlasco C, Faini A, Makil E, Bilo G, Pengo M, Beaney T, Xia X, Borghi C, Poulter NR, Tocci G, Galletti F, Desideri G, Veglio F, Ferri C, Parati G. Nation-wide hypertension screening in Italy: data from May Measurements Month 2017-Europe. *Eur Heart J Suppl.* 2019;21(Suppl D):D66-D70.

**255)** Desideri G, Ferri C. Aspirin for primary prevention in elderly hypertensive patients: to treat or not to treat? *J Hypertens.* 2019;37(6):1154-1156.